Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib
出版年份 2021 全文链接
标题
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib
作者
关键词
SIRT2, Sorafenib, Synthetic lethality, Breast cancer, Combination therapy
出版物
PHARMACOLOGICAL RESEARCH
Volume 177, Issue -, Pages 106050
出版商
Elsevier BV
发表日期
2021-12-30
DOI
10.1016/j.phrs.2021.106050
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- The role of SIRT2 in cancer: a novel therapeutic target
- (2020) Guangyuan Chen et al. INTERNATIONAL JOURNAL OF CANCER
- Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells
- (2020) Sreeja Dattachoudhury et al. ONCOLOGY
- The Clinical Significance of SIRT2 in Malignancies: A Tumor Suppressor or an Oncogene?
- (2020) Lin Zhang et al. Frontiers in Oncology
- Tip60- and sirtuin 2-regulated MARCKS acetylation and phosphorylation are required for diabetic embryopathy
- (2019) Penghua Yang et al. Nature Communications
- Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquinone
- (2019) M. Zakariyyah Aumeeruddy et al. CANCER
- SIRT2: Controversy and multiple roles in disease and physiology
- (2019) Yan Wang et al. AGEING RESEARCH REVIEWS
- Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation
- (2019) Sathid Aimjongjun et al. BMC CANCER
- Synthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors
- (2019) Nadia A. Khalil et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer
- (2018) Naveen K.R. Chalakur-Ramireddy et al. BIOSCIENCE REPORTS
- Structural optimization and structure-activity relationship studies of N -phenyl-7,8-dihydro-6 H -pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants
- (2018) Jiao Yang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- X-ray crystal structure guided discovery of new selective, substrate-mimicking sirtuin 2 inhibitors that exhibit activities against non-small cell lung cancer cells
- (2018) Ling-Ling Yang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- An overview of Sirtuins as potential therapeutic target: Structure, function and modulators
- (2018) Yijie Wang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Curcumin in combination with anti-cancer drugs: A nanomedicine review
- (2018) Harshul Batra et al. PHARMACOLOGICAL RESEARCH
- SIRT2 mediated antitumor effects of shikonin on metastatic colorectal cancer
- (2017) Li-Li Zhang et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Sorafenib for the treatment of breast cancer
- (2017) Giuseppe Bronte et al. EXPERT OPINION ON PHARMACOTHERAPY
- Potent mechanism-based sirtuin-2-selective inhibition by an in situ-generated occupant of the substrate-binding site, “selectivity pocket” and NAD+-binding site
- (2017) Paolo Mellini et al. Chemical Science
- A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models
- (2017) Nannan Zhang et al. Oncotarget
- Combination therapy in combating cancer
- (2017) Reza Bayat Mokhtari et al. Oncotarget
- Identification of a Selective SIRT2 Inhibitor and Its Anti-breast Cancer Activity
- (2016) Asad Ali Shah et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity
- (2016) Hui Jing et al. CANCER CELL
- Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial
- (2016) Denise A. Yardley et al. Clinical Breast Cancer
- Human sirtuins: Structures and flexibility
- (2016) Lionel Sacconnay et al. JOURNAL OF STRUCTURAL BIOLOGY
- The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer
- (2016) Wenhui Zhou et al. Cell Reports
- Sirtuins in Epigenetic Regulation
- (2015) Hui Jing et al. CHEMICAL REVIEWS
- Design, Synthesis, and Structure–Activity Relationship Studies of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as a New Class of Src Inhibitors with Potent Activities in Models of Triple Negative Breast Cancer
- (2015) Chun-Hui Zhang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer
- (2014) L Bazzola et al. BRITISH JOURNAL OF CANCER
- SIRT2 induces the checkpoint kinase BubR1 to increase lifespan
- (2014) B. J. North et al. EMBO JOURNAL
- Benzimidazoles as new scaffold of sirtuin inhibitors: Green synthesis, in vitro studies, molecular docking analysis and evaluation of their anti-cancer properties
- (2014) Yeong Keng Yoon et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells
- (2014) Di Zhao et al. JOURNAL OF CLINICAL INVESTIGATION
- Chroman-4-one- and Chromone-Based Sirtuin 2 Inhibitors with Antiproliferative Properties in Cancer Cells
- (2014) Tina Seifert et al. JOURNAL OF MEDICINAL CHEMISTRY
- SIRT2 regulates tumour hypoxia response by promoting HIF-1α hydroxylation
- (2014) K-S Seo et al. ONCOGENE
- Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells
- (2014) Young Hwa Soung et al. Scientific Reports
- SIRT2: Tumour suppressor or tumour promoter in operable breast cancer?
- (2013) Liane M. McGlynn et al. EUROPEAN JOURNAL OF CANCER
- SIRT2 directs the replication stress response through CDK9 deacetylation
- (2013) H. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Tyrosine Kinase Inhibitors Gefitinib, Lapatinib and Sorafenib Induce Rapid Functional Alterations in Breast Cancer Cells
- (2010) S. Carloni et al. CURRENT CANCER DRUG TARGETS
- Mechanisms of drug combinations: interaction and network perspectives
- (2009) Jia Jia et al. NATURE REVIEWS DRUG DISCOVERY
- A novel method based on click chemistry, which overcomes limitations of cell cycle analysis by classical determination of BrdU incorporation, allowing multiplex antibody staining
- (2008) Paolo Cappella et al. CYTOMETRY PART A
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now